Gilead, GSK-ViiV Move Ahead With Long-Acting HIV Options Following Early-Stage Readouts

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their long-acting antivirals after touting positive early-stage results.